The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Talquetamab: GPRC5D-CD3 bispecific antibody in R/R myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the preliminary results of a Phase I study (NCT03399799) of talquetamab, a bispecific antibody that targets GPRC5D and CD3, in relapsed/refractory multiple myeloma patients. High GPRC5D expression is limited to myeloma cells, so talquetamab is able to induce their targeted T-cell killing. The first-in-human dose-escalation study was designed to determine the recommended Phase II dose of the treatment and its safety. The results show encouraging early efficacy results in a highly pretreated myeloma population and a manageable safety profile, with low rates of treatment-related neurotoxicity and high-grade cytokine release syndrome. A maximum tolerated dose has not yet been reached, and dose-escalation is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
